Apyx Medical Corporation $APYX Shares Bought by Silverberg Bernstein Capital Management LLC

Key Points

• Silverberg Bernstein Capital Management LLC increased its stake in Apyx Medical Corporation by 38.7%, owning 896,736 shares after acquiring an additional 250,167 shares during the second quarter.
• Apyx Medical reported a quarterly EPS of ($0.09), in line with analyst estimates, and a revenue of $11.37 million, slightly below projections of $11.69 million.
• The company's stock has a market capitalization of $80.56 million and trades at $2.13, with a one-year high of $2.73 and a low of $0.76.

Silverberg Bernstein Capital Management LLC raised its position in Apyx Medical Corporation (NASDAQ:APYX - Free Report) by 38.7% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 896,736 shares of the company's stock after buying an additional 250,167 shares during the quarter. Apyx Medical comprises about 1.4% of Silverberg Bernstein Capital Management LLC's holdings, making the stock its 19th largest position. Silverberg Bernstein Capital Management LLC owned approximately 2.37% of Apyx Medical worth $2,018,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Strategic Advisors LLC purchased a new stake in shares of Apyx Medical during the 1st quarter worth $27,000. Joel Isaacson & Co. LLC purchased a new stake in shares of Apyx Medical during the 1st quarter worth $28,000. Northern Trust Corp boosted its position in shares of Apyx Medical by 27.9% during the 4th quarter. Northern Trust Corp now owns 132,251 shares of the company's stock worth $209,000 after purchasing an additional 28,865 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of Apyx Medical by 130.6% during the 4th quarter. Citadel Advisors LLC now owns 66,355 shares of the company's stock worth $105,000 after purchasing an additional 37,582 shares in the last quarter. Finally, Kingsview Wealth Management LLC boosted its position in shares of Apyx Medical by 29.5% during the 1st quarter. Kingsview Wealth Management LLC now owns 175,095 shares of the company's stock worth $240,000 after purchasing an additional 39,850 shares in the last quarter. 55.33% of the stock is owned by institutional investors and hedge funds.

Apyx Medical Price Performance

Shares of NASDAQ APYX opened at $2.13 on Tuesday. The firm has a market capitalization of $80.56 million, a P/E ratio of -4.73 and a beta of 1.43. Apyx Medical Corporation has a one year low of $0.76 and a one year high of $2.73. The company's fifty day moving average is $2.10 and its two-hundred day moving average is $1.64. The company has a debt-to-equity ratio of 4.61, a quick ratio of 3.95 and a current ratio of 4.72.

Apyx Medical (NASDAQ:APYX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $11.37 million for the quarter, compared to analyst estimates of $11.69 million. Apyx Medical had a negative net margin of 37.11% and a negative return on equity of 158.22%. Apyx Medical has set its FY 2025 guidance at EPS. Analysts forecast that Apyx Medical Corporation will post -0.68 EPS for the current fiscal year.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.

Want to see what other hedge funds are holding APYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apyx Medical Corporation (NASDAQ:APYX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.